Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Glioblastoma

Disease Progression

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Temozolomide

APG-157 is an orally administered drug encased in a hydrogel pastille.

Arms:

* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)
* Progression post TMZ (will receive APG-157 only)
* Ongoing Optune (will receive concurrent Optune + APG-157)
* Progression post Optune (will receive APG-157 only)

APG-157

Dedra L Preece, BS

Theresa Strakos, BS

Ekokobe Fonkem, DO

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

Glioblastoma patients with disease recurrence after primary, currently approved primary treatments have limited options. Therefore, this expanded access trial is designed to test a new therapeutic option for these patients.

Patients who have progressed on a combination of both Temozolomide and Tumor Treating Field (Optune) or as single treatment Temozolomide (TMZ) OR Tumor Treating Fields (Optune) are eligible to receive APG-157. During APG-157 dosing, TMZ or Optune may be concurrently given at the decision of the Principal Investigator. APG-157 will be given until disease progression or intolerance by the patient.

Radiation followed by adjuvant Temozolomide for 6 to 12 months which is a current standard of care (SOC). Upon progression of this disease after SOC treatment, there are very limited further options for these patients. This expanded access administration will evaluate the potential of APG-157, a novel drug under development for head and neck cancer, as a potential treatment for these recurrent glioblastoma patients.

Brief Description of Objectives:

* Improve six-month progression-free survival (PFS) and overall survival (OS) of the patients eligible for the treatment under Expanded Access protocol.
* Improvement in Quality of Life
* Achievements of above two objectives without any Serious Adverse Events (SAEs) and adverse drug-drug interactions.

Brief Description of Plans for Efficacy Assessment:

* Improvement in Quality of Life
* Efficacy will be assessed using Imaging (objective tumor response using Response Assessment in Neuro-Oncology criteria (RANO), hematological assessment, and tolerance.

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Aveta Biomics, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Treatment of Recurrent GBM With APG-157 Via Expanded Access	NCT05551013	Glioblastoma Glioblastoma Mu...	APG-157	18 Years - 85 Years	Aveta Biomics, Inc.
Treatment of Recurrent GBM With APG-157 Via Expanded Access	NCT05551013	Glioblastoma Glioblastoma Mu...	APG-157	18 Years - 85 Years	Aveta Biomics, Inc.

Spots Global Cancer Trial Database for tumor treating field